LCG
TVRD

Lisanti Capital Growth’s Tvardi Therapeutics TVRD Stock Holding History

Lisanti Capital Growth’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,423
Closed -$1.49M – 165
2022
Q3 		$1.49M Buy
+4,423
New +$1.6M 0.2% 105

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lisanti Capital Growth's TVRD Position: Q4 2022 in Review

Lisanti Capital Growth sold out of Tvardi Therapeutics (TVRD) in Q4 2022, closing a stake of 4,423 shares — an estimated $1.49M sold.

Lisanti Capital Growth first reported a position in TVRD in Q3 2022 and held it in 1 quarter. The position peaked at $1.49M in Q3 2022. 160 funds tracked by Wall St. Rank hold TVRD as of Q4 2022.

  • Lisanti Capital Growth reported no remaining Tvardi Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Lisanti Capital Growth sold 4,423 Tvardi Therapeutics shares in Q4 2022, an estimated $1.49M.
  • Lisanti Capital Growth first reported a position in Tvardi Therapeutics in Q3 2022 and held it in 1 quarter.
  • Lisanti Capital Growth's Tvardi Therapeutics position peaked at $1.49M in Q3 2022.
  • 160 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2022.

Based on Lisanti Capital Growth's 13F filing for Q4 2022, filed 6 Feb 2023.